Bio Products Laboratory Ltd

SMECompany No. 00734036

Has won 27 UK public-sector contracts worth £73.0m across 9 buyers, primarily NHS England.

⇄ Compare peers ⇩ Export ↗ Share

Active contracts

no new awards in 30d

Contracted (12m)

—

no data

Public buyers

stable this month

Top buyer share

95%

NHS England

Buyer concentration

Each block sized by share of total award value. A dominant block signals dependency on one buyer.

Severe concentration. Top buyer alone = 95% of revenue.

NHS England

£69.6m

95%

Department of Health and Social Care (DHSC)

£3.3m

Hull University Teaching Hospitals NHS Trust

£139k

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

—

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency

—

Other (4 buyers)

£0

Contracts won · 27 total · 22 active · 5 expired

Every contract award published under the Procurement Act.

Sort

Title	Buyer	Award type	Value	Awarded	Status
Human Normal Immunoglobulin and Anti-D Immunoglobulin	NHS England	Shared contract	£64.3m lot total · 7 suppliers	23 Jun 2021	expired
Human Albumin	NHS England	Shared contract	£5.3m lot total · 5 suppliers	18 Mar 2021	expired
Contract for the supply of immunoglobulins	Department of Health and Social Care (DHSC)	Direct contract	£3.3m	29 Mar 2021	expired
NATIONAL FRAMEWORK AGREEMENT FOR THE SUPPLY OF HUMAN NORMAL IMMUNOGLOBULIN AND ANTI-D IMMUNOGLOBULIN	Hull University Teaching Hospitals NHS Trust	Shared contract	£94k lot total · 2 suppliers	28 Jun 2021	expired
NHS NATIONAL FRAMEWORK AGREEMENT AGREEMENT FOR HUMAN ALBUMIN SOLUTION (HAS)	Hull University Teaching Hospitals NHS Trust	Shared contract	£45k lot total · 5 suppliers	26 Apr 2021	expired
Hepatitis B immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
Tetanus immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925a Hepatitis B immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925a Hepatitis B immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925b Tetanus immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925c Anti Rabies immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925c Anti Rabies immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
NP34925b Tetanus immunoglobulin intramuscular use (IM)	The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)	Direct contract	—	—	active
Immunoglobulins (2025)	Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency	Direct contract	—	—	active
Immunoglobulins (2025)	Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency	Direct contract	—	—	active

Showing 1–15 of 27

Bio Products Laboratory Ltd

Buyer concentration

Contracts won · 27 total · 22 active · 5 expired

Top buyers · by total award value

Category mix — CPV divisions

Geographic spread

Modifications received · scope growth on existing wins

Compliance scorecard

Financial health

Company information

Corporate structure

Companies House data

Peer suppliers

News mentions

Compliance scorecard

Financial health

Company information

Corporate structure

Bio Products Laboratory Ltd

Companies House data

Why Capita's public-sector share keeps slipping — and who's eating it

The 12 frameworks Capita bid on last year (and lost 8)

Is BPO concentration back? A supplier-risk deep-dive